There have been reports of noninfectious pneumonitis (including some with pulmonary hypertension as a secondary event), infections, and renal failure (including acute renal failure) in patients...
Diane: A Case Study of HR+, HER2-Negative Advanced Breast Cancer Following Progression on NSAI Therapy
Ingrid Mayer, MD
Breast Cancer Specialist
Vanderbilt University Medical Center
Allan Lipton, MD
Professor of Oncology
Milton S. Hershey Medical Center
Information About Stomatitis Associated With the Use of AFINITOR for Advanced HR+, HER2-Negative Breast Cancer
Joyce O'Shaughnessy, MD (With Josie Divers, RN)
Monica: A Case Study of HR+, HER2-Negative Breast Cancer Metastasis During Adjuvant Anastrozole Therapy
William Gradishar, MD
Professor of Medicine
Director, Maggie Daley Center for Women’s Cancer Care
Virginia Kaklamani, MD
University of Texas Health Science Center
San Antonio, Texas
HER2, human epidermal growth factor receptor 2; HR+, hormone receptor-positive; NSAI, nonsteroidal aromatase inhibitor.
AFINITOR is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole.
Important Safety Information
AFINITOR is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients.
Angioedema With Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors
Impaired Wound Healing
Laboratory Tests and Monitoring
Please see full Prescribing Information.